Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan

28th June 2019 Uncategorised 0

In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added another indication this week that could rake in $1 billion for its portfolio—but there’s a catch.

More: Alexion nabs potential B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan
Source: fierce